Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis

Takeshi Suzuki, Yuta Suzuki, Jun Okuda, Takuya Kurazumi, Tomohiro Suhara, Tomomi Ueda, Hiromasa Nagata, Hiroshi Morisaki

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Despite recent advances in medical care, mortality due to sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains high. Fluid resuscitation and vasopressors are the first-line treatment for sepsis in order to optimize hemodynamic instability caused by vasodilation and increased vascular permeability. However, these therapies, aimed at maintaining blood pressure and blood flow to vital organs, could have deleterious cardiac effects, as cardiomyocyte damage occurs in the early stages of sepsis. Recent experimental and clinical studies have demonstrated that a number of factors contribute to sepsis-induced cardiac dysfunction and the degree of cardiac dysfunction is one of the major prognostic factors of sepsis. Therefore, strategies to prevent further cardiomyocyte damage could be of crucial importance in improving the outcome of sepsis. Among many factors causing sepsis-induced cardiac dysfunction, sympathetic nerve overstimulation, due to endogenous elevated catecholamine levels and exogenous catecholamine administration, is thought to play a major role. β-adrenergic blockade therapy is widely used for ischemic heart disease and chronic heart failure and in the prevention of cardiovascular events in high-risk perioperative patients undergoing major surgery. It has also been shown to restore cardiac function in experimental septic animal models. In a single-center randomized controlled trial, esmolol infusion in patients with septic shock with persistent tachycardia reduced the 28-day mortality. Furthermore, it is likely that β-adrenergic blockade therapy may result in further beneficial effects in patients with sepsis, such as the reduction of inflammatory cytokine production, suppression of hypermetabolic status, maintenance of glucose homeostasis, and improvement of coagulation disorders. Recent accumulating evidence suggests that β-adrenergic blockade could be an attractive therapy to improve the prognosis of sepsis. We await a large multicenter randomized clinical trial to confirm the beneficial effects of β-adrenergic blockade therapy in sepsis, of which mortality is still high.

Original languageEnglish
Article number22
JournalJournal of Intensive Care
Volume5
Issue number1
DOIs
Publication statusPublished - 2017 Mar 3

Fingerprint

Adrenergic Agents
Sepsis
Therapeutics
Cardiac Myocytes
Catecholamines
Mortality
Randomized Controlled Trials
Capillary Permeability
Septic Shock
Tachycardia
Vasodilation
Resuscitation
Myocardial Ischemia
Homeostasis
Animal Models
Heart Failure
Hemodynamics
Maintenance
Cytokines
Blood Pressure

Keywords

  • Sepsis
  • Sepsis-induced cardiac dysfunction
  • β-adrenergic blockade therapy

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis. / Suzuki, Takeshi; Suzuki, Yuta; Okuda, Jun; Kurazumi, Takuya; Suhara, Tomohiro; Ueda, Tomomi; Nagata, Hiromasa; Morisaki, Hiroshi.

In: Journal of Intensive Care, Vol. 5, No. 1, 22, 03.03.2017.

Research output: Contribution to journalReview article

@article{f3bbb1e1adda41f887d4d62fb6f447d2,
title = "Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis",
abstract = "Despite recent advances in medical care, mortality due to sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains high. Fluid resuscitation and vasopressors are the first-line treatment for sepsis in order to optimize hemodynamic instability caused by vasodilation and increased vascular permeability. However, these therapies, aimed at maintaining blood pressure and blood flow to vital organs, could have deleterious cardiac effects, as cardiomyocyte damage occurs in the early stages of sepsis. Recent experimental and clinical studies have demonstrated that a number of factors contribute to sepsis-induced cardiac dysfunction and the degree of cardiac dysfunction is one of the major prognostic factors of sepsis. Therefore, strategies to prevent further cardiomyocyte damage could be of crucial importance in improving the outcome of sepsis. Among many factors causing sepsis-induced cardiac dysfunction, sympathetic nerve overstimulation, due to endogenous elevated catecholamine levels and exogenous catecholamine administration, is thought to play a major role. β-adrenergic blockade therapy is widely used for ischemic heart disease and chronic heart failure and in the prevention of cardiovascular events in high-risk perioperative patients undergoing major surgery. It has also been shown to restore cardiac function in experimental septic animal models. In a single-center randomized controlled trial, esmolol infusion in patients with septic shock with persistent tachycardia reduced the 28-day mortality. Furthermore, it is likely that β-adrenergic blockade therapy may result in further beneficial effects in patients with sepsis, such as the reduction of inflammatory cytokine production, suppression of hypermetabolic status, maintenance of glucose homeostasis, and improvement of coagulation disorders. Recent accumulating evidence suggests that β-adrenergic blockade could be an attractive therapy to improve the prognosis of sepsis. We await a large multicenter randomized clinical trial to confirm the beneficial effects of β-adrenergic blockade therapy in sepsis, of which mortality is still high.",
keywords = "Sepsis, Sepsis-induced cardiac dysfunction, β-adrenergic blockade therapy",
author = "Takeshi Suzuki and Yuta Suzuki and Jun Okuda and Takuya Kurazumi and Tomohiro Suhara and Tomomi Ueda and Hiromasa Nagata and Hiroshi Morisaki",
year = "2017",
month = "3",
day = "3",
doi = "10.1186/s40560-017-0215-2",
language = "English",
volume = "5",
journal = "Journal of Intensive Care",
issn = "2052-0492",
publisher = "Springer International Publishing AG",
number = "1",

}

TY - JOUR

T1 - Sepsis-induced cardiac dysfunction and β-adrenergic blockade therapy for sepsis

AU - Suzuki, Takeshi

AU - Suzuki, Yuta

AU - Okuda, Jun

AU - Kurazumi, Takuya

AU - Suhara, Tomohiro

AU - Ueda, Tomomi

AU - Nagata, Hiromasa

AU - Morisaki, Hiroshi

PY - 2017/3/3

Y1 - 2017/3/3

N2 - Despite recent advances in medical care, mortality due to sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains high. Fluid resuscitation and vasopressors are the first-line treatment for sepsis in order to optimize hemodynamic instability caused by vasodilation and increased vascular permeability. However, these therapies, aimed at maintaining blood pressure and blood flow to vital organs, could have deleterious cardiac effects, as cardiomyocyte damage occurs in the early stages of sepsis. Recent experimental and clinical studies have demonstrated that a number of factors contribute to sepsis-induced cardiac dysfunction and the degree of cardiac dysfunction is one of the major prognostic factors of sepsis. Therefore, strategies to prevent further cardiomyocyte damage could be of crucial importance in improving the outcome of sepsis. Among many factors causing sepsis-induced cardiac dysfunction, sympathetic nerve overstimulation, due to endogenous elevated catecholamine levels and exogenous catecholamine administration, is thought to play a major role. β-adrenergic blockade therapy is widely used for ischemic heart disease and chronic heart failure and in the prevention of cardiovascular events in high-risk perioperative patients undergoing major surgery. It has also been shown to restore cardiac function in experimental septic animal models. In a single-center randomized controlled trial, esmolol infusion in patients with septic shock with persistent tachycardia reduced the 28-day mortality. Furthermore, it is likely that β-adrenergic blockade therapy may result in further beneficial effects in patients with sepsis, such as the reduction of inflammatory cytokine production, suppression of hypermetabolic status, maintenance of glucose homeostasis, and improvement of coagulation disorders. Recent accumulating evidence suggests that β-adrenergic blockade could be an attractive therapy to improve the prognosis of sepsis. We await a large multicenter randomized clinical trial to confirm the beneficial effects of β-adrenergic blockade therapy in sepsis, of which mortality is still high.

AB - Despite recent advances in medical care, mortality due to sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains high. Fluid resuscitation and vasopressors are the first-line treatment for sepsis in order to optimize hemodynamic instability caused by vasodilation and increased vascular permeability. However, these therapies, aimed at maintaining blood pressure and blood flow to vital organs, could have deleterious cardiac effects, as cardiomyocyte damage occurs in the early stages of sepsis. Recent experimental and clinical studies have demonstrated that a number of factors contribute to sepsis-induced cardiac dysfunction and the degree of cardiac dysfunction is one of the major prognostic factors of sepsis. Therefore, strategies to prevent further cardiomyocyte damage could be of crucial importance in improving the outcome of sepsis. Among many factors causing sepsis-induced cardiac dysfunction, sympathetic nerve overstimulation, due to endogenous elevated catecholamine levels and exogenous catecholamine administration, is thought to play a major role. β-adrenergic blockade therapy is widely used for ischemic heart disease and chronic heart failure and in the prevention of cardiovascular events in high-risk perioperative patients undergoing major surgery. It has also been shown to restore cardiac function in experimental septic animal models. In a single-center randomized controlled trial, esmolol infusion in patients with septic shock with persistent tachycardia reduced the 28-day mortality. Furthermore, it is likely that β-adrenergic blockade therapy may result in further beneficial effects in patients with sepsis, such as the reduction of inflammatory cytokine production, suppression of hypermetabolic status, maintenance of glucose homeostasis, and improvement of coagulation disorders. Recent accumulating evidence suggests that β-adrenergic blockade could be an attractive therapy to improve the prognosis of sepsis. We await a large multicenter randomized clinical trial to confirm the beneficial effects of β-adrenergic blockade therapy in sepsis, of which mortality is still high.

KW - Sepsis

KW - Sepsis-induced cardiac dysfunction

KW - β-adrenergic blockade therapy

UR - http://www.scopus.com/inward/record.url?scp=85014415104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014415104&partnerID=8YFLogxK

U2 - 10.1186/s40560-017-0215-2

DO - 10.1186/s40560-017-0215-2

M3 - Review article

AN - SCOPUS:85014415104

VL - 5

JO - Journal of Intensive Care

JF - Journal of Intensive Care

SN - 2052-0492

IS - 1

M1 - 22

ER -